PMID- 36074511
OWN - NLM
STAT- MEDLINE
DCOM- 20220912
LR  - 20220912
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 21
IP  - 9
DP  - 2022 Sep 1
TI  - Efficacy and Tolerability of a Retinoid Eye Cream for Fine to Moderate Wrinkles 
      of the Periorbital Region.
PG  - 932-937
LID - 10.36849/JDD.6815 [doi]
AB  - INTRODUCTION: The periorbital region is susceptible to premature skin aging and 
      among the first areas to manifest age-related changes. Retinoids are highly 
      effective but can be irritating, limiting use in this vulnerable area. A 
      hydrating formulation comprised of a double-conjugated retinoid/alpha hydroxy 
      acid (lactic acid; AHARet-EM) has been developed to address photoaging of the 
      periorbital area. This study evaluated the efficacy, tolerability, and subject 
      satisfaction of nightly application of AHARet-EM, and a regimen that included 
      application of a peptide-rich eye cream (InF-E; AM) and AHARet-EM (PM). DESIGN: A 
      12-week, dual-center, open-label study evaluated nightly application of AHARet-EM 
      in subjects 35 to 65 years of age with fine to moderate lines/wrinkles in the 
      periorbital area (3-7 score based on the Fitzpatrick Classification Wrinkle Scale 
      [FCWS]). A subset of subjects applied AHARet-EM (PM) and InF-E (AM). Investigator 
      assessments at baseline and weeks 4, 8, and 12 were based on the 9-point FCWS for 
      lines/wrinkles (1 [Fine Wrinkles] to 9 [Deep Wrinkles]) and a 6-point scale (0 
      [None] to 5 [Severe]) for texture, erythema, and under-eye darkness, puffiness, 
      and dryness. Subject satisfaction and adverse events (AEs) were captured over 12 
      weeks. RESULTS: Twenty-six subjects, Fitzpatrick skin type III-VI, completed the 
      study. Subjects applying AHARet-EM (n=16) demonstrated significant improvements 
      from baseline at week 12 in the appearance of lines/wrinkles (33%; P<.0001), 
      texture (37%, P<.0001), erythema (37%, P=.004), under-eye darkness (41%; 
      P<.001), puffiness (55%, P<.0001) and dryness (94%, P<.0001). 
      Significant improvements from baseline were demonstrated in subjects using the 
      AM/PM regimen (n=10) at week 12 in the appearance of texture (33%; P=.002), 
      erythema (68%; P=.001), under-eye darkness (32%; P=.007), puffiness (64%; P=.01) 
      and dryness (90%; P<.0001). No AEs occurred related/possibly related to use of 
      the study products. High levels of subject satisfaction were reported over 12 
      weeks. CONCLUSION: Nightly application of a hydrating, double-conjugated retinoid 
      eye cream demonstrated significant improvements in the appearance of 
      lines/wrinkles, under-eye darkness, puffiness, and dryness of the periorbital 
      area at week 12. Morning application of a peptide-rich eye cream afforded 
      additional benefits. The study products were non-irritating, and subjects 
      reported high levels of satisfaction throughout the study. J Drugs Dermatol. 
      2022;21(9):932-937. doi:10.36849/JDD.6815.
FAU - Kaufman, Joely
AU  - Kaufman J
FAU - Callender, Valerie
AU  - Callender V
FAU - Young, Cherie
AU  - Young C
FAU - Jones, Patricia
AU  - Jones P
FAU - Wortzman, Mitchell
AU  - Wortzman M
FAU - Nelson, Diane
AU  - Nelson D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 0 (Emollients)
RN  - 0 (Retinoids)
SB  - IM
MH  - Emollients
MH  - Erythema/etiology
MH  - Humans
MH  - Retinoids/adverse effects
MH  - *Skin Aging
MH  - Skin Cream/adverse effects
MH  - Treatment Outcome
EDAT- 2022/09/09 06:00
MHDA- 2022/09/14 06:00
CRDT- 2022/09/08 11:40
PHST- 2022/09/08 11:40 [entrez]
PHST- 2022/09/09 06:00 [pubmed]
PHST- 2022/09/14 06:00 [medline]
AID - S1545961622P0932X [pii]
AID - 10.36849/JDD.6815 [doi]
PST - ppublish
SO  - J Drugs Dermatol. 2022 Sep 1;21(9):932-937. doi: 10.36849/JDD.6815.